The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9289398 B1

Date of Patent:

Mar. 22, 2016

Filed:

Mar. 29, 2007

Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith

Applicants:

Neil Almstead, Princeton, NJ (US);

Guangming Chen, Bridgewater, NJ (US);

Samit Hirawat, Chatham, NJ (US);

Peter Seongwoo Hwang, Edison, NJ (US);

Gary M. Karp, Princeton Junction, NJ (US);

Langdon Miller, Lebanon, NJ (US);

Young-choon Moon, Belle Meade, NJ (US);

Hongyu Ren, Dayton, NJ (US);

James J. Takasugi, Lawrenceville, NJ (US);

Ellen M. Welch, Califon, NJ (US);

Richard G. Wilde, Somerville, NJ (US);

Paul Kennedy, Brighton, MI (US);

Inventors:

Neil Almstead, Princeton, NJ (US);

Guangming Chen, Bridgewater, NJ (US);

Samit Hirawat, Chatham, NJ (US);

Peter Seongwoo Hwang, Edison, NJ (US);

Gary M. Karp, Princeton Junction, NJ (US);

Langdon Miller, Lebanon, NJ (US);

Young-Choon Moon, Belle Meade, NJ (US);

Hongyu Ren, Dayton, NJ (US);

James J. Takasugi, Lawrenceville, NJ (US);

Ellen M. Welch, Califon, NJ (US);

Richard G. Wilde, Somerville, NJ (US);

Paul Kennedy, Brighton, MI (US);

Assignee:

PTC Therapeutics, Inc., South Plainfield, NJ (US);

Attorney:

Jones Day

Primary Examiner:

Sarah Pihonak

Assistant Examiner:

Jason A Deck

Int. Cl.

CPC ...

A61K 31/4245 (2006.01); A61P 21/00 (2006.01); A61K 31/00 (2006.01); A61K 31/40 (2006.01); A61K 31/41 (2006.01); A61K 31/4162 (2006.01); A61K 31/44 (2006.01); A61K 31/46 (2006.01); A61K 31/5377 (2006.01); A61K 31/496 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/4439 (2006.01); A61K 31/519 (2006.01); A61K 31/498 (2006.01); A61K 31/53 (2006.01); A61K 31/506 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/433 (2006.01); A61K 31/421 (2006.01); A61K 31/415 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/42 (2006.01); A61K 31/4164 (2006.01); A61K 31/34 (2006.01); A61K 31/381 (2006.01); A61K 31/4196 (2006.01); A61P 11/00 (2006.01); A61P 7/00 (2006.01); A61P 25/00 (2006.01); A61P 13/12 (2006.01); A61P 27/02 (2006.01);

U.S. Cl.

CPC ...

A61K 31/00 (2013.01); A61K 31/40 (2013.01); A61K 31/41 (2013.01); A61K 31/4162 (2013.01); A61K 31/44 (2013.01); A61K 31/46 (2013.01);

Abstract

The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

Find Patent Forward Citations